메뉴 바로가기: 주메뉴 바로가기; 컨텐츠 바로가기

Products

PRODUCTS

BIOLOGICS

Project code name

PCH250

Competitiveness

Promotion of joint development with European or Japanese partners
Plan to promote global phase III clinical trials
Continuous growth of the macular degeneration market due to global aging
Macular degeneration is incurable, but requires regular treatment
Secure competitiveness by establishing high productivity and stable production process
Confirmation of excellent quality equivalence between the reference drug EYLEA® and the Pangen’s biosimilar

Major Functions
and Characteristics

Treatment for neovascular age-related macular degeneration
Treatment for visual impairment caused by retinal vein occlusive macular edema
Treatment for visual impairment caused by diabetic macular edema
Treatment for visual impairment caused by choroidal neovascularization due to pathologic myopia
Development stage: Preclinical completion (2020.09)